AFFY Affymax Inc.
- 0.34 P/E
- 7.18 P/S
- 103.33 P/B
- 0.3 EPS
- 0 / 0% Dividend
- 503,146.00 Avg. Vol.
- 37.00M Shares
- 3.7M Market Cap.
Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. The company is developing Hematide, which is in Phase III clinical trials for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood ...
NephrologyNews.com - Jul 1, 2014
Wall Street Journal - Jun 30, 2014
Forbes - Jul 23, 2014
Zacks.com - Jun 30, 2014
Seeking Alpha - Jul 17, 2014
Reuters Key Development - Jun 24, 2014
Reuters Key Development - Jun 13, 2014
Reuters Key Development - Jun 7, 2013
Reuters Key Development - Apr 26, 2013
Reuters Key Development - Apr 13, 2013